Sign in

    David Seynnaeve • Degroof Petercam

    David Seynnaeve is a Biotech Equity Analyst at Banque Degroof Petercam, specializing in the biotechnology and healthcare sectors with a focus on European companies. He covers major firms including argenx, Galapagos, Oncodesign Precision Medicine, and participates in earnings calls and research for emerging biotech leaders. Seynnaeve joined Degroof Petercam in March 2021 after previously working as an analyst at LSP Management Group and Degroof Petercam Gestion, and holds a PhD, highlighting his scientific credentials. While detailed third-party performance metrics or rankings are not publicly documented, he is a recognized expert contributing sponsored research and financial projections for several public companies in the life sciences space.

    David Seynnaeve's questions to Galapagos NV (GLPG) leadership

    David Seynnaeve's questions to Galapagos NV (GLPG) leadership • Q1 2025

    Question

    David Seynnaeve asked for a more precise timeline on when the PAPILIO-1 patient enrollment will be completed and whether top-line results in 2026 are more likely in the first or second half of the year.

    Answer

    CEO Paulus Stoffels stated that the PAPILIO-1 study is still recruiting in its Phase 1 portion and will soon start the Phase 2 expansion. While he confirmed top-line data would be reported in 2026, he said the company could not yet provide more specific guidance on whether it would be in H1 or H2, but would provide an update in a future call.

    Ask Fintool Equity Research AI